Keyword: Calithera Biosciences
Scientists at Vanderbilt University found that a glutaminase inhibitor improved the anticancer activity of CAR-T cells.
Two commonly mutated genes in lung cancer may make some tumor cells especially vulnerable to an experimental drug from Calithera Biosciences.
Incyte has paid $53 million upfront for Calithera Biosciences’ small molecule arginase inhibitor CB-1158.
Californian CRO ProTrials Research has been picked by fellow CA-based cancer biotech Calithera Biosciences to help it run an early-stage trial for its oncology candidate.